Sudeep Pharma is a manufacturer of calcium-based inorganic chemicals used in pharmaceuticals, nutraceuticals, food, feed, oral care, and industrial applications. It earns revenue by supplying pharma excipients, specialty ingredients, nutritional supplements, and chemical solutions to global and domestic clients. Its products serve diverse end-use sectors including tablets, toothpaste, food fortification, plastics, rubber, and coatings.

The Company is led by Promoter, i.e., SUJIT JAYSUKH BHAYANI, AVANI SUJIT BHAYANI, SHANIL SUJIT BHAYANI, SUJEET JAYSUKH BHAYANI HUF, RIVA RESOURCES PRIVATE LIMITED AND BHAYANI FAMILY TRUST

The Revenues from operations for the Period ended on Jun 30 2025 and Fiscals ended on Mar 31, 2025, 2024 and 2023 were â‚¹ 1,300.76 Million, ₹ 5,113.28 Million, â‚¹ 4,653.78 Million, and ₹ 4,382.59 Million, The EBITDA for the Period ended on Jun 30 2025, 2025 and Fiscals ended on Mar 31, 2025, 2024 and 2023 were â‚¹ 485.70 Million, ₹ 1,992.81 Million, â‚¹ 1,877.55 Million, and ₹ 986.42 Million, The Profit after Tax for the Period ended on Jun 30 2025, 2025 and Fiscals ended on Mar 31, 2025, 2024 and 2023 were were â‚¹ 312.70 Million, ₹ 1,386.91 Million, â‚¹ 1,331.87 Million, and ₹ 623.21 Million, respectively. This indicates a steady growth in financial performance.

The Company Key Performance Indicates the pre-issue EPS of â‚¹12.78and post-issue EPS of ₹12.28 for FY25. The pre-issue P/E ratio is46.40x, while the post-issue P/E ratio is48.29x against the Industry P/E ratio is NA The company's ROE for FY25 is 28.13% and RoNW is 27.88%. The Annualised EPS is ₹11.07x and P/E is 53.55x. These metrics suggest that the IPO is Fully priced.

The Grey Market Premium (GMP) of  Sudeep Pharma  showing listing gains of  0 %.Given the company's financial performance and the valuation of the IPO, we recommend  Investors to Avoid to the Sudeep Pharma Limited IPO for Listing gain or Long Term Purposes.